glp-1 obesity drugs pipeline Top and Diabetes Medications Transforming U.S. Pharma Market Solving the Unmet Needs in

Sharing a 94% structural homology with native human GLP-1, Semaglutide is distinguished by three modifications: 1) amino-acid substitutions at position 8 (alanine to -aminoisobutyric acid or Aib) and position 34 (lysine to arginine), and acylation of the lysine in position 26 with a spacer consisting of two 8-amino-3,6-dioxaoctanoic acid (ADO) moieties, a glutamic acid moiety, and a C-18 fatty di-acid side chain (Lau et al., 2015)

MicroRNAs in Obesity-Associated Disorders: The Role of Exercise Training

Comparison of the Effects of Liraglutide, Tirzepatide, and Retatrutide on Diabetic Kidney Disease in Db/Db Mice

Fuentes N, Silveyra P